Covered recipient · General Payments record
AMADO J ZURITA-SAAVEDRA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2019–2024
$51,128.04
- Reported across 45 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $2,100.00 | 1 |
| Travel and Lodging | $1,807.26 | 7 |
| Food and Beverage | $801.72 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Exelixis Inc. | $4,260.96 | 11 |
| PFIZER INC. | $160.86 | 2 |
| Janssen Scientific Affairs, LLC | $136.08 | 1 |
| Astellas Pharma Global Development | $121.98 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $29.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma Global Development | $121.98 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132965355 | CMS |
| Exelixis Inc. | $174.00 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138554780 | CMS |
| Exelixis Inc. | $60.95 | 07/09/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1138554784 | CMS |
| Exelixis Inc. | $407.94 | 07/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1138554782 | CMS |
| Exelixis Inc. | $217.00 | 07/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1138554786 | CMS |
| Exelixis Inc. | $66.11 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138554788 | CMS |
| Exelixis Inc. | $113.59 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138554792 | CMS |
| Exelixis Inc. | $217.00 | 07/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1138554796 | CMS |
| Exelixis Inc. | $766.26 | 07/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1138554798 | CMS |
| Exelixis Inc. | $70.00 | 07/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1138554800 | CMS |
| Exelixis Inc. | $68.11 | 07/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1138554790 | CMS |
| Exelixis Inc. | $2,100.00 | 07/25/2024 | Honoraria | Undisputed | 01/23/2026 | 1138554794 | CMS |
| Janssen Scientific Affairs, LLC | $136.08 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078859979 | CMS |
| Novartis Pharmaceuticals Corporation | $29.10 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087440450 | CMS |
| PFIZER INC. | $135.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131468641 | CMS |
| PFIZER INC. | $25.86 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131261780 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.